RYDAPT (Novartis Pharmaceuticals Corporation)
Welcome to the PulseAid listing for the RYDAPT drug offered from Novartis Pharmaceuticals Corporation. This Kinase Inhibitor [EPC],Receptor Tyrosine Kinase Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Novartis Pharmaceuticals Corporation |
| NON-PROPRIETARY NAME: | RYDAPT |
| SUBSTANCE NAME: | MIDOSTAURIN |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Kinase Inhibitor [EPC],Receptor Tyrosine Kinase Inhibitors [MoA] |
| ROUTE: | ORAL |
| DOSAGE FORM: | CAPSULE, LIQUID FILLED |
| MARKETING CATEGORY NAME: | NDA |
| START MARKETING DATE: | 2017-04-28 |
| END MARKETING DATE: | 0000-00-00 |
RYDAPT HUMAN PRESCRIPTION DRUG Details:
| Item Description | RYDAPT from Novartis Pharmaceuticals Corporation |
| LABELER NAME: | Novartis Pharmaceuticals Corporation |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 25(mg/1) |
| START MARKETING DATE: | 2017-04-28 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 0078-0698_11fa3fc9-6776-49a6-b1c1-653f627c3e58 |
| PRODUCT NDC: | 0078-0698 |
| APPLICATION NUMBER: | NDA207997 |
Other MIDOSTAURIN Pharmaceutical Manufacturers / Labelers:
